Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
51
OCGN Quote, Financials, Valuation and Earnings
Last price:
$1.24
Seasonality move
:
29.55%
Day range:
$1.20 - $1.26
52-week range:
$0.52 - $1.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
68.06x
P/B ratio:
109.64x
Volume:
3.3M
Avg. volume:
3.2M
1-year change:
40.4%
Market cap:
$387.3M
Revenue:
$4.1M
EPS (TTM):
-$0.22
Analysts' Opinion
-
Consensus RatingOcugen, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.00, Ocugen, Inc. has an estimated upside of 625.81% from its current price of $1.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $1.24.
Fair Value
-
According to the consensus of 3 analysts, Ocugen, Inc. has 625.81% upside to fair value with a price target of $9.00 per share.
OCGN vs. S&P 500
-
Over the past 5 trading days, Ocugen, Inc. has overperformed the S&P 500 by 4.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ocugen, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ocugen, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Ocugen, Inc. reported revenues of $1.8M.
Earnings Growth
-
Ocugen, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ocugen, Inc. reported earnings per share of -$0.07.
Enterprise value:
387.7M
EV / Invested capital:
10.62x
Price / LTM sales:
68.06x
EV / EBIT:
--
EV / Revenue:
72.19x
PEG ratio (5yr expected):
-0.51x
EV / Free cash flow:
-7.24x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2M
Return On Assets:
-99.74%
Net Income Margin (TTM):
-1192.18%
Return On Equity:
-345.08%
Return On Invested Capital:
-139.38%
Operating Margin:
-1005.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $5.5M | $4.7M | $5.4M | $1.1M | $1.8M | |
| Gross Profit | $4.8M | $3.2M | $2M | $523K | $802K | |
| Operating Income | -$77.4M | -$52.4M | -$59.8M | -$13.3M | -$17.6M | |
| EBITDA | -$76.7M | -$50.9M | -$56.4M | -$12.6M | -$16.7M | |
| Diluted EPS | -$0.32 | -$0.20 | -$0.22 | -$0.05 | -$0.07 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $113.5M | $107.5M | $56.6M | $40.7M | $37.6M | |
| Total Assets | $116.3M | $116.2M | $74.7M | $61.9M | $57.6M | |
| Current Liabilities | $6.2M | $14.9M | $11.1M | $15.8M | $20.4M | |
| Total Liabilities | $9.2M | $20.9M | $16.3M | $21.3M | $54.1M | |
| Total Equity | $107.1M | $95.3M | $58.4M | $40.6M | $3.5M | |
| Total Debt | $3.1M | $6M | $5.9M | $6.3M | $32.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$67.7M | -$43.1M | -$53.4M | -$11.3M | -$12.9M | |
| Cash From Investing | -$9.5M | -$6.1M | -$289K | -$507K | -$86K | |
| Cash From Financing | $29M | $34.7M | $47.5M | $34.8M | $18.5M | |
| Free Cash Flow | -$77.4M | -$49.2M | -$53.5M | -$11.8M | -$13M | |
OCGN
Sector
Market Cap
$387.3M
$28.8M
Price % of 52-Week High
65.26%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-4.62%
-1.32%
1-Year Price Total Return
40.4%
-20.64%
Beta (5-Year)
4.540
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.20
200-day SMA
Buy
Level
$1.03
Bollinger Bands (100)
Sell
Level
1.01 - 1.53
Chaikin Money Flow
Sell
Level
-18.7M
20-day SMA
Buy
Level
$1.22
Relative Strength Index (RSI14)
Sell
Level
46.01
ADX Line
Sell
Level
24.23
Williams %R
Sell
Level
-17.1271
50-day SMA
Sell
Level
$1.45
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-32.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.6371)
Sell
CA Score
(Annual)
Level (-3.892)
Buy
Beneish M-Score
(Annual)
Level (-4.4514)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (5.467)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Stock Forecast FAQ
In the current month, OCGN has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OCGN average analyst price target in the past 3 months is $9.00.
-
Where Will Ocugen, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ocugen, Inc. share price will rise to $9.00 per share over the next 12 months.
-
What Do Analysts Say About Ocugen, Inc.?
Analysts are divided on their view about Ocugen, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ocugen, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Ocugen, Inc.'s Price Target?
The price target for Ocugen, Inc. over the next 1-year time period is forecast to be $9.00 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OCGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ocugen, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OCGN?
You can purchase shares of Ocugen, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ocugen, Inc. shares.
-
What Is The Ocugen, Inc. Share Price Today?
Ocugen, Inc. was last trading at $1.24 per share. This represents the most recent stock quote for Ocugen, Inc.. Yesterday, Ocugen, Inc. closed at $1.24 per share.
-
How To Buy Ocugen, Inc. Stock Online?
In order to purchase Ocugen, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get OCGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
OCGN
Sector
P/E ratio
--
23.71x
PEG ratio
-0.51x
-0.01x
P/B ratio
109.64x
1.84x
Price / LTM sales
68.06x
1.60x
Growth Metrics
OCGN
Sector
Revenue growth
54.23%
4.85%
Earnings growth
-41.63%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.06
-$0.20
Profitability
OCGN
Sector
Profitability FY 2024
$2.1M
$3.6M
Return on invested capital
-139.38%
-30.98%
Return on assets
-99.74%
-27.62%
Return on equity
-345.08%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
4
Balance Sheet
OCGN
Sector
Total cash
$32.6M
$27.2M
Short term investments
--
$25.7M
Total assets
$83.3M
$79.7M
Long term debt
$32.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
